JP2016522168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522168A5 JP2016522168A5 JP2016506649A JP2016506649A JP2016522168A5 JP 2016522168 A5 JP2016522168 A5 JP 2016522168A5 JP 2016506649 A JP2016506649 A JP 2016506649A JP 2016506649 A JP2016506649 A JP 2016506649A JP 2016522168 A5 JP2016522168 A5 JP 2016522168A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- amino acid
- disease
- hvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 65
- 208000006673 asthma Diseases 0.000 claims description 25
- 102000003816 Interleukin-13 Human genes 0.000 claims description 23
- 108090000176 Interleukin-13 Proteins 0.000 claims description 23
- 102000004388 Interleukin-4 Human genes 0.000 claims description 21
- 108090000978 Interleukin-4 Proteins 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims description 3
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims description 2
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 18
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 18
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 13
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 12
- 206010039085 Rhinitis allergic Diseases 0.000 claims 12
- 201000010105 allergic rhinitis Diseases 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 230000035772 mutation Effects 0.000 claims 11
- 230000001404 mediated effect Effects 0.000 claims 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims 9
- 206010016654 Fibrosis Diseases 0.000 claims 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 9
- 201000008937 atopic dermatitis Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 208000019425 cirrhosis of liver Diseases 0.000 claims 9
- 230000004761 fibrosis Effects 0.000 claims 9
- 208000005017 glioblastoma Diseases 0.000 claims 9
- 208000011231 Crohn disease Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 201000004624 Dermatitis Diseases 0.000 claims 6
- 206010014561 Emphysema Diseases 0.000 claims 6
- 208000027004 Eosinophilic disease Diseases 0.000 claims 6
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 6
- 206010006451 bronchitis Diseases 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 6
- 208000027866 inflammatory disease Diseases 0.000 claims 6
- 230000002685 pulmonary effect Effects 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 210000003979 eosinophil Anatomy 0.000 claims 5
- 208000023504 respiratory system disease Diseases 0.000 claims 5
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 4
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 3
- 208000028185 Angioedema Diseases 0.000 claims 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 3
- 206010003645 Atopy Diseases 0.000 claims 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims 3
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 3
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 3
- 208000015943 Coeliac disease Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 206010012442 Dermatitis contact Diseases 0.000 claims 3
- 206010014950 Eosinophilia Diseases 0.000 claims 3
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 3
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 3
- 206010015218 Erythema multiforme Diseases 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 208000006968 Helminthiasis Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 3
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 3
- 206010054949 Metaplasia Diseases 0.000 claims 3
- 208000000112 Myalgia Diseases 0.000 claims 3
- 208000000592 Nasal Polyps Diseases 0.000 claims 3
- 241000208125 Nicotiana Species 0.000 claims 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 3
- 206010030113 Oedema Diseases 0.000 claims 3
- 241000243981 Onchocerca Species 0.000 claims 3
- 206010035664 Pneumonia Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010068956 Respiratory tract inflammation Diseases 0.000 claims 3
- 208000034189 Sclerosis Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 208000024780 Urticaria Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 208000027207 Whipple disease Diseases 0.000 claims 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 3
- 201000009961 allergic asthma Diseases 0.000 claims 3
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 201000009267 bronchiectasis Diseases 0.000 claims 3
- 208000019748 bullous skin disease Diseases 0.000 claims 3
- 208000023819 chronic asthma Diseases 0.000 claims 3
- 208000007451 chronic bronchitis Diseases 0.000 claims 3
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 3
- 208000010247 contact dermatitis Diseases 0.000 claims 3
- 208000010643 digestive system disease Diseases 0.000 claims 3
- 206010057271 eosinophilic colitis Diseases 0.000 claims 3
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 3
- 201000001561 eosinophilic gastritis Diseases 0.000 claims 3
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims 3
- 230000001667 episodic effect Effects 0.000 claims 3
- 208000024711 extrinsic asthma Diseases 0.000 claims 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 3
- 210000002175 goblet cell Anatomy 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 201000010659 intrinsic asthma Diseases 0.000 claims 3
- 230000015689 metaplastic ossification Effects 0.000 claims 3
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 3
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 3
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims 2
- 206010014664 Endocardial fibrosis Diseases 0.000 claims 2
- 208000005577 Gastroenteritis Diseases 0.000 claims 2
- -1 IgE Proteins 0.000 claims 2
- 108010073816 IgE Receptors Proteins 0.000 claims 2
- 102100039897 Interleukin-5 Human genes 0.000 claims 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 2
- 230000002327 eosinophilic effect Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 101150104383 ALOX5AP gene Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 claims 1
- 101001019600 Homo sapiens Interleukin-17 receptor B Proteins 0.000 claims 1
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 claims 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 claims 1
- 101000585365 Homo sapiens Sulfotransferase 2A1 Proteins 0.000 claims 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims 1
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 claims 1
- 101001050476 Homo sapiens Tyrosine-protein kinase ITK/TSK Proteins 0.000 claims 1
- 102000009438 IgE Receptors Human genes 0.000 claims 1
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims 1
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims 1
- 102100035014 Interleukin-17 receptor B Human genes 0.000 claims 1
- 102100039064 Interleukin-3 Human genes 0.000 claims 1
- 102000017761 Interleukin-33 Human genes 0.000 claims 1
- 108010067003 Interleukin-33 Proteins 0.000 claims 1
- 102000010786 Interleukin-5 Receptors Human genes 0.000 claims 1
- 108010038484 Interleukin-5 Receptors Proteins 0.000 claims 1
- 102000000585 Interleukin-9 Human genes 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 102000010682 Interleukin-9 Receptors Human genes 0.000 claims 1
- 108010038414 Interleukin-9 Receptors Proteins 0.000 claims 1
- 101100236114 Mus musculus Lrrfip1 gene Proteins 0.000 claims 1
- 102100031789 Myeloid-derived growth factor Human genes 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 claims 1
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 102100029867 Sulfotransferase 2A1 Human genes 0.000 claims 1
- 102000000551 Syk Kinase Human genes 0.000 claims 1
- 108010016672 Syk Kinase Proteins 0.000 claims 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims 1
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000016366 nasal cavity polyp Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 description 13
- 230000004071 biological effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 description 3
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229950002183 lebrikizumab Drugs 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 2
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 102000019207 human interleukin-13 Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361808748P | 2013-04-05 | 2013-04-05 | |
| US61/808,748 | 2013-04-05 | ||
| PCT/US2014/032998 WO2014165771A2 (en) | 2013-04-05 | 2014-04-04 | Anti-il-4 antibodies and bispecific antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016522168A JP2016522168A (ja) | 2016-07-28 |
| JP2016522168A5 true JP2016522168A5 (https=) | 2017-05-25 |
Family
ID=51659356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016506649A Pending JP2016522168A (ja) | 2013-04-05 | 2014-04-04 | 抗ｉｌ−４抗体及び二重特異性抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160207995A1 (https=) |
| EP (1) | EP2981286A4 (https=) |
| JP (1) | JP2016522168A (https=) |
| KR (1) | KR20150139905A (https=) |
| CN (1) | CN105307676A (https=) |
| AR (1) | AR095774A1 (https=) |
| BR (1) | BR112015024553A2 (https=) |
| CA (1) | CA2905223A1 (https=) |
| HK (1) | HK1220919A1 (https=) |
| MX (1) | MX2015013901A (https=) |
| RU (1) | RU2015141529A (https=) |
| TW (1) | TW201518321A (https=) |
| WO (1) | WO2014165771A2 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3083682B1 (en) | 2013-12-20 | 2024-04-17 | F. Hoffmann-La Roche AG | Dual specific antibodies |
| JP2017507939A (ja) * | 2014-02-21 | 2017-03-23 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用 |
| US10112994B2 (en) | 2014-11-05 | 2018-10-30 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
| MX382952B (es) | 2014-11-05 | 2025-03-13 | Genentech Inc | Métodos de producción de proteínas de cadena doble en bacterias. |
| EP3271723A1 (en) * | 2015-03-16 | 2018-01-24 | F. Hoffmann-La Roche AG | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
| AU2016252773B2 (en) | 2015-04-24 | 2022-06-02 | Genentech, Inc. | Multispecific antigen-binding proteins |
| EP3337819B1 (en) * | 2015-08-20 | 2024-02-21 | F. Hoffmann-La Roche AG | Method of purifying for producing recombinant polypeptides using fkpa |
| TWI703158B (zh) * | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| CN105664178B (zh) * | 2015-09-24 | 2019-08-20 | 洪健 | Syk作为肝纤维化/硬化治疗靶点的应用 |
| IL299072A (en) * | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods for using them |
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| CN107446045A (zh) * | 2016-07-22 | 2017-12-08 | 北京天广实生物技术股份有限公司 | 一种抗her2的抗体、其药物组合物及用途 |
| US10377833B2 (en) | 2016-07-22 | 2019-08-13 | Beijing Mabworks Biotech Co., Ltd. | Bispecific anti-HER2 antibody |
| KR102557643B1 (ko) | 2016-09-23 | 2023-07-20 | 제넨테크, 인크. | 아토피성 피부염을 치료하기 위한 il-13 길항제의 용도 |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| CA3052796A1 (en) * | 2017-02-07 | 2018-08-16 | Children's Hospital Medical Center | Treatment of asthma with cysteamine |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| CN109593773B (zh) * | 2018-11-22 | 2021-07-30 | 北京利德曼生化股份有限公司 | 一种应用酵母表达系统表达可溶性生长刺激表达基因2蛋白的方法 |
| CN110746507B (zh) | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
| MA55204A (fr) | 2019-03-06 | 2022-01-12 | Regeneron Pharma | Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer |
| CN113597328B (zh) | 2019-03-21 | 2025-10-31 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| WO2020242989A1 (en) * | 2019-05-24 | 2020-12-03 | Sanofi | Methods for treating systemic sclerosis |
| KR102697769B1 (ko) * | 2020-09-14 | 2024-08-23 | 아주대학교산학협력단 | 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도 |
| CA3199586A1 (en) * | 2020-11-23 | 2022-05-27 | Samantha J. Busfield | Antigen-binding molecules and uses thereof |
| WO2023044313A1 (en) | 2021-09-15 | 2023-03-23 | Dermira, Inc. | Il-13 inhibitors for the treatment of prurigo nodularis |
| AU2022425608A1 (en) | 2021-12-30 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
| US20240117030A1 (en) * | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| IL317083A (en) | 2022-06-17 | 2025-01-01 | Apogee Biologics Inc | Antibodies that bind interleukin 13 and methods of use |
| CN116854821A (zh) * | 2022-08-15 | 2023-10-10 | 海徕科(北京)生物技术有限公司 | IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途 |
| WO2025026216A1 (zh) * | 2023-07-28 | 2025-02-06 | 江苏恒瑞医药股份有限公司 | 一种含有糖皮质激素的抗体药物偶联物的药物组合物 |
| JP7668943B2 (ja) * | 2023-08-30 | 2025-04-25 | ファイザー・インク | 多重特異性抗体およびその使用 |
| JP2025036273A (ja) * | 2023-08-30 | 2025-03-14 | ファイザー・インク | 多重特異性抗体およびその使用 |
| AR134102A1 (es) * | 2023-10-12 | 2025-12-03 | Innovent Biologics Suzhou Co Ltd | ANTICUERPOS ANTI-IL-4Ra Y USOS DE LOS MISMOS |
| WO2025128984A1 (en) | 2023-12-14 | 2025-06-19 | Dermira, Inc. | Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps |
| WO2025128990A1 (en) | 2023-12-14 | 2025-06-19 | Dermira, Inc. | Il-13 antibodies for the treatment of perennial allergic rhinitis |
| TW202600591A (zh) | 2024-03-01 | 2026-01-01 | 美商德米拉股份有限公司 | 用於治療發炎後皮膚色素過多或色素過少之ｉｌ—１３抗體 |
| WO2025264972A1 (en) * | 2024-06-21 | 2025-12-26 | Apogee Therapeutics, Inc. | Antibodies that bind il-4r alpha and antibodies that bind |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2085983T3 (es) * | 1989-12-20 | 1996-06-16 | Schering Corp | Antagonistas de anticuerpos de la interleuquina-4 humana. |
| US5597710A (en) * | 1994-03-10 | 1997-01-28 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| DK1399484T3 (da) * | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| CN101260156A (zh) * | 2002-06-28 | 2008-09-10 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| US20070104710A1 (en) * | 2002-06-28 | 2007-05-10 | Domants Limited | Ligand that has binding specificity for IL-4 and/or IL-13 |
| SG10201404273QA (en) * | 2003-12-23 | 2014-10-30 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| CN101076542A (zh) * | 2004-09-13 | 2007-11-21 | 伊沃詹尼克斯有限公司 | 特异性针对肝细胞癌和其他癌的抗体及其用途 |
| EP3050963B1 (en) * | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| AU2009254501B2 (en) * | 2008-06-05 | 2014-07-31 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
| MX2011010166A (es) * | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
| EP2435481A1 (en) * | 2009-05-28 | 2012-04-04 | Glaxo Group Limited | Il-13 binding protein |
| CN102946906B (zh) * | 2010-04-23 | 2015-07-15 | 弗·哈夫曼-拉罗切有限公司 | 生产异源多聚体蛋白质 |
-
2014
- 2014-04-04 AR ARP140101485A patent/AR095774A1/es unknown
- 2014-04-04 WO PCT/US2014/032998 patent/WO2014165771A2/en not_active Ceased
- 2014-04-04 BR BR112015024553A patent/BR112015024553A2/pt not_active Application Discontinuation
- 2014-04-04 EP EP14779789.8A patent/EP2981286A4/en not_active Withdrawn
- 2014-04-04 JP JP2016506649A patent/JP2016522168A/ja active Pending
- 2014-04-04 CN CN201480031775.3A patent/CN105307676A/zh active Pending
- 2014-04-04 RU RU2015141529A patent/RU2015141529A/ru not_active Application Discontinuation
- 2014-04-04 HK HK16109143.9A patent/HK1220919A1/zh unknown
- 2014-04-04 MX MX2015013901A patent/MX2015013901A/es unknown
- 2014-04-04 KR KR1020157031454A patent/KR20150139905A/ko not_active Withdrawn
- 2014-04-04 CA CA2905223A patent/CA2905223A1/en not_active Abandoned
- 2014-04-07 TW TW103112741A patent/TW201518321A/zh unknown
-
2015
- 2015-09-18 US US14/858,251 patent/US20160207995A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016522168A5 (https=) | ||
| RU2015141529A (ru) | Антитела и биспецифические антитела к il-4 и их применение | |
| US10738112B2 (en) | Anti-human interleukin-17A monoclonal antibody | |
| ES2817756T3 (es) | Proteínas de unión a interleuquina-13 | |
| JP2020124205A (ja) | Ｉｌ−２３ａ及びｔｎｆ−アルファを標的とする化合物ならびにその使用 | |
| KR20230004576A (ko) | 항인간 인터루킨-4수용체 α항체의 제조방법과 용도 | |
| JP2019502692A (ja) | 抗ｔｌ１ａ／抗ｔｎｆ−アルファ二重特異性抗原結合タンパク質及びその使用 | |
| JP2014500009A5 (https=) | ||
| JP2017532037A5 (https=) | ||
| JP2014237671A5 (https=) | ||
| CN106211782A (zh) | 抗体‑fynomer缀合物 | |
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| US20150266954A1 (en) | Il-21 antibodies | |
| RU2013110874A (ru) | Антитела против il-18r1 и их применения | |
| JP7842101B2 (ja) | ＩＬ－６およびＴＮＦ－αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド | |
| JP2019527194A5 (https=) | ||
| JP2012524524A5 (https=) | ||
| AU2016369307A1 (en) | Multi-specific antibody molecules having specificity for TNF-alpha, IL-17A and IL-17F | |
| ES2877376T3 (es) | Anticuerpos para IL-17C | |
| JP2016520595A5 (https=) | ||
| WO2019120060A1 (zh) | 结合人il-5的单克隆抗体、其制备方法和用途 | |
| KR20170127407A (ko) | 특발성 폐섬유증의 치료 방법 | |
| CN115551539A (zh) | 自身免疫性病症中的抗bcma疗法 | |
| WO2024020590A4 (en) | Antigen binding molecules targeting thymic stromal lymphopoietin (tslp) | |
| JPWO2023116925A5 (https=) |